Can amiodarone cause bradycardia (low heart rate) in a patient with a history of cardiac issues?

Amiodarone and Bradycardia

Yes, amiodarone definitively causes bradycardia (low heart rate) in patients with cardiac issues, occurring in approximately 4.9% of patients receiving IV amiodarone and up to 32% during oral loading, with the risk being substantially higher in patients with pre-existing conduction disorders. 1, 2

Mechanism of Bradycardia

Amiodarone causes bradycardia through multiple electrophysiologic mechanisms 3:

• Depression of AV nodal conduction via calcium channel and beta-receptor blockade
• Suppression of sinus node automaticity through sympatholytic effects
• Consistent heart rate reduction both at rest and during exercise

The bradycardia risk exists regardless of the dose administered 4, 1.

Incidence and Risk Stratification

Overall Incidence

• IV amiodarone: Drug-related bradycardia occurs in 4.9% of patients 1
• Oral loading phase: Sinus bradycardia in 32% of patients 2
• Oral maintenance phase: Bradycardia in 11.2% of patients 2

High-Risk Populations

Patients with pre-existing conduction disorders face substantially elevated risk 3, 5:

• 24% incidence of symptomatic bradycardia in patients with baseline conduction abnormalities 5
• Specific high-risk conditions include:
  • First-degree AV block 5
  • Right or left bundle branch block 5
  • Pre-existing sinus node dysfunction 5
  • Asymptomatic sinus arrest or sinoatrial block 5

In contrast, patients without pre-existing conduction disorders had 0% incidence of symptomatic bradycardia (p < 0.0005) 5.

Gender-Specific Risk

Amiodarone-associated bradycardia requiring permanent pacemaker implantation is more common in women than in men 6, 7, 3.

Clinical Manifestations

Bradycardia severity ranges from 6, 1, 5:

• Asymptomatic heart rate slowing
• Symptomatic bradycardia requiring intervention
• Second- or third-degree AV block (in patients with pre-existing first-degree block or bundle branch block) 5
• Intermittent sinus arrest or SA block (in patients with previous sinus node dysfunction) 5
• Bradycardia requiring permanent pacemaker implantation 6, 7
• Progressive and terminal bradycardia (rare but documented) 1

Management Algorithm

Before Initiating Amiodarone

Assess for absolute contraindications 4, 1:

• Bradycardia without pacemaker in place
• Second- or third-degree heart block without pacemaker
• Significant conduction system disease

Use extreme caution if heart rate ≤57 bpm 4:

• Amiodarone is relatively contraindicated unless:
  • A pacemaker is present, OR
  • The situation is immediately life-threatening with no safer alternatives

Evaluate baseline conduction 4, 3:

• Obtain baseline ECG to assess for conduction disorders
• Document baseline heart rate
• Identify patients with first-degree AV block, bundle branch blocks, or sinus node dysfunction

During IV Administration

Continuous ECG monitoring is mandatory 7, 4:

• Monitor heart rate continuously
• Watch for AV conduction abnormalities
• Assess QT prolongation
• Monitor PR interval, QRS duration, and QT interval 7

If bradycardia develops during IV infusion 1:

1. Slow the infusion rate immediately
2. If bradycardia persists, discontinue amiodarone
3. Consider temporary pacemaker insertion in patients with known predisposition to bradycardia or AV block 1

During Oral Therapy

Monitor heart rate weekly initially 7, 8:

• Check pulse rate
• Use event recorder, OR
• Obtain office ECG tracings

Reduce doses of concomitant rate-control agents approximately 6 weeks after starting amiodarone 3, 9:

• Reduce beta-blockers, calcium channel blockers, or other rate-control medications
• Discontinue rate-control medications entirely if excessive bradycardia develops 9

Reassess ECG after each dose change 7, 8:

• Measure PR interval (with amiodarone)
• Measure QRS duration
• Measure QT interval

Critical Drug Interactions Potentiating Bradycardia

Concomitant medications that slow AV conduction create additive effects and significantly increase bradycardia risk 3, 1:

• Beta-blockers (e.g., propranolol) 1
• Calcium channel blockers (e.g., verapamil, diltiazem) 1
• Digoxin 3
• Dexmedetomidine (case report of cardiac arrest when co-administered) 10

Amiodarone should be used with caution in patients receiving these agents because of possible potentiation of bradycardia, sinus arrest, and AV block 1. If necessary, amiodarone can continue after insertion of a pacemaker in patients with severe bradycardia or sinus arrest 1.

Common Pitfalls and How to Avoid Them

1. Overlooking pre-existing conduction disorders: Always obtain baseline ECG before initiating amiodarone, as patients with even minor conduction abnormalities have 24% risk of symptomatic bradycardia 5.

2. Failing to reduce concomitant rate-control medications: The dose of beta-blockers, calcium channel blockers, or digoxin should be reduced when heart rate slows after amiodarone initiation and stopped if rate slows excessively 7, 8.

3. Inadequate monitoring during loading: Bradycardia is most common during the loading phase (32% with oral loading), requiring weekly heart rate monitoring 2.

4. Missing the gender-specific risk: Women have higher rates of amiodarone-associated bradycardia requiring pacemaker implantation 6, 7, 3.

5. Not having pacemaker availability: Patients with known predisposition to bradycardia or AV block should be treated in a setting where a temporary pacemaker is available 1.